Guardant Health’s ECLIPSE study data demonstrates efficacy of Shield blood test

The company states: “Guardant Health announced that results from the ECLIPSE study showing the effectiveness of its ShieldTM blood test for detecting colorectal cancer in average-risk adults will be published in the March 14 issue of The New England Journal of Medicine. One of the largest studies of its kind, ECLIPSE is a 20,000+-patient registrational study to evaluate the performance of Shield compared to a screening colonoscopy. The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA”. Co-CEO AmirAli Talasaz says: “Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant. We believe the publication of the ECLIPSE study in The New England Journal of Medicine, one of the world’s leading medical journals, is an endorsement of the quality of our clinical data and the potential value of the Shield test. We are confident that offering an accurate blood test has the potential to significantly reduce preventable colorectal cancer deaths.”